Who is sponsoring NCT01757431?

NCT01757431 is sponsored by Alexion Pharmaceuticals, Inc..

What drugs are being tested in NCT01757431?

Interventions in NCT01757431: Eculizumab.

What condition does NCT01757431 study?

NCT01757431 studies Atypical Hemolytic Uremic Syndrome (aHUS).

Is NCT01757431 still recruiting?

NCT01757431 is currently completed. Last updated 10 March 2017.

Last reviewed 2017-03-10 · How we verify

NCT01757431

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Completed Phase 2 Last updated 10 March 2017

What this trial tests

Phase 2 trial testing Eculizumab in Atypical Hemolytic Uremic Syndrome (aHUS) in 2 participants. Completed in 25 September 2013.

Timeline

16 May 2012

Primary endpoint
24 September 2013

25 September 2013

Quick facts

Lead sponsor	Alexion Pharmaceuticals, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	16 May 2012
Primary completion	24 September 2013
Estimated completion	25 September 2013
Sites	2 locations across Japan

Drugs / interventions tested

Eculizumab (ECULIZUMAB) — full drug profile →

Conditions studied

Atypical Hemolytic Uremic Syndrome (aHUS) — all drugs for Atypical Hemolytic Uremic Syndrome (aHUS) →

Sponsor

Alexion Pharmaceuticals, Inc. — full company profile →

Who can join

Eligibility, any sex, with Atypical Hemolytic Uremic Syndrome (aHUS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Protocol is intended to characterize the overall safety and tolerability of eculizumab in this population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for atypical haemolytic uraemic syndrome.
Pugh D, O'Sullivan ED, Duthie FA, Masson P, et al · · 2021 · cited 13× · PMID 33783815 · DOI 10.1002/14651858.cd012862.pub2

Verify or expand the search:

Other trials of Eculizumab

Trials testing the same drug.

NCT06764160 — Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG · Phase 3 · completed
NCT06513338 — Complement C5 mAb in the Treatment of Anti-GBM Disease · Phase 2 · completed
NCT05876351 — Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China · Phase 3 · completed
NCT05886244 — Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China · Phase 3 · completed
NCT05131204 — Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment · Phase 3 · terminated

Other recruiting trials for Atypical Hemolytic Uremic Syndrome (aHUS)

Currently open trials in the same condition.

NCT06312644 — Study of Ultomiris® (Ravulizumab) Safety in Pregnancy · recruiting

Other Alexion Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06015750 — Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia · Phase 4 · withdrawn
NCT07352423 — Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants · Phase 1 · recruiting
NCT07221838 — A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab · Phase 4 · recruiting
NCT07413250 — Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis o · active not recruiting
NCT07308574 — Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01757431 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexion Pharmaceuticals, Inc.
Last refreshed: 10 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01757431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing